MM-133: HORIZON (OP-106): Melflufen Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to Pomalidomide and/or an Anti-CD38 Monoclonal Antibody (mAb) – Final Primary Analysis
Paul G. Richardson(Harvard University), María‐Victoria Mateos(Hospital Clínico San Carlos), Alessandra Larocca(Cornell University), Agne Paner(Rush University Medical Center), Adrían Alegre(Hospital Universitario de La Princesa), Johan Harmenberg(Oncopeptides (Sweden)), Noemí Puig(Instituto de Investigación Biomédica de Salamanca), Xavier Leleu(Inserm), Joan Biade(Hospital Clínic de Barcelona), Omar Nadeem(Harvard University), Albert Oriol(Institut Català d'Oncologia), Anastasios Raptis(University of Pittsburgh), Cyrille Touzeau(Centre National de la Recherche Scientifique), Hani Hassoun(Memorial Sloan Kettering Cancer Center), Michèle Cavo(Unknown), Sara Thuresson(Oncopeptides (Sweden)), Paula Rodríguez‐Otero(Clinica Universidad de Navarra), Jakob Obermüller(Oncopeptides (Sweden)), Catriona Byrne(Oncopeptides (Sweden)), Amitabha Mazumder(NYU Langone Health), Christopher Maisel(Baylor Medical Center at Garland), John W. Hiemenz(University of Florida), Maxim Norkin(Centre Hospitalier Universitaire Vaudois)
Cited by 0
Related Papers
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
|New England Journal of Medicine|2003|2.6k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k